Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
- PMID: 33296054
- PMCID: PMC7726073
- DOI: 10.1186/s40658-020-00339-2
Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
Abstract
Purpose: Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (teff) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points.
Methods: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after 177Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the teff and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively.
Results: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated teff were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points.
Conclusion: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit.
Keywords: 177Lu-DOTATATE; Dosimetry; Extrapolation; Kidney; Neuroendocrine tumors; Simplifications.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures







Similar articles
-
Personalized radiation dosimetry for PRRT-how many scans are really required?EJNMMI Phys. 2020 May 11;7(1):26. doi: 10.1186/s40658-020-00293-z. EJNMMI Phys. 2020. PMID: 32394075 Free PMC article.
-
Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.EJNMMI Phys. 2015 Dec;2(1):24. doi: 10.1186/s40658-015-0127-y. Epub 2015 Oct 24. EJNMMI Phys. 2015. PMID: 26501825 Free PMC article.
-
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.J Nucl Med. 2015 Feb;56(2):177-82. doi: 10.2967/jnumed.114.148437. Epub 2015 Jan 15. J Nucl Med. 2015. PMID: 25593115
-
Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance.Acta Oncol. 2018 Apr;57(4):516-521. doi: 10.1080/0284186X.2017.1378431. Epub 2017 Sep 18. Acta Oncol. 2018. PMID: 28920501
-
Developments in 177Lu-based radiopharmaceutical therapy and dosimetry.Front Chem. 2023 Jul 31;11:1218670. doi: 10.3389/fchem.2023.1218670. eCollection 2023. Front Chem. 2023. PMID: 37583569 Free PMC article. Review.
Cited by
-
Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour.EJNMMI Phys. 2024 Feb 5;11(1):14. doi: 10.1186/s40658-024-00620-8. EJNMMI Phys. 2024. PMID: 38315270 Free PMC article.
-
Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects.J Pers Med. 2022 Feb 2;12(2):205. doi: 10.3390/jpm12020205. J Pers Med. 2022. PMID: 35207693 Free PMC article. Review.
-
Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection.J Nucl Med. 2023 Sep;64(9):1463-1470. doi: 10.2967/jnumed.122.265338. Epub 2023 Jul 27. J Nucl Med. 2023. PMID: 37500260 Free PMC article.
-
On the reduction of imaging time-points for dosimetry in radionuclide therapy.EJNMMI Phys. 2025 Feb 6;12(1):14. doi: 10.1186/s40658-025-00721-y. EJNMMI Phys. 2025. PMID: 39909959 Free PMC article.
-
Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.Z Med Phys. 2023 Feb;33(1):70-81. doi: 10.1016/j.zemedi.2022.06.004. Epub 2022 Aug 10. Z Med Phys. 2023. PMID: 35961809 Free PMC article.
References
-
- Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–2423. doi: 10.1200/JCO.2010.33.7873. - DOI - PubMed
-
- Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging. 2010;54:92–99. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous